Autophagy and mitophagy machinery

The autophagy and mitophagy machinery represents a complex network of proteins responsible for the degradation and recycling of cellular components and damaged mitochondria. Autophagy is a survival mechanism that allows cells to adapt to nutrient deprivation by sequestering cytoplasmic material into double-membrane autophagosomes, which then fuse with lysosomes for degradation (Mizushima, N., & Komatsu, M. (2011). Cell, 147(4), 728-741). Mitophagy is a specialized form of this process that selectively targets dysfunctional mitochondria, often mediated by the PINK1 kinase and Parkin ubiquitin ligase, to prevent oxidative stress and cell death (Youle, R. J., & Narendra, D. P. (2011). Nature Reviews Molecular Cell Biology, 12(1), 9-14). Dysregulation of these pathways is a hallmark of neurodegenerative diseases like Parkinson's, where defective mitophagy leads to the accumulation of toxic mitochondria, and cancer, where autophagy can act as a double-edged sword by either preventing tumor initiation or supporting the survival of established tumors (Pickrell, A. M., & Youle, R. J. (2015). Neuron, 85(2), 257-273; Levy, J. M., et al. (2017). Nature Reviews Cancer, 17(9), 528-542). Therapeutic strategies include the use of mTOR inhibitors to stimulate autophagy or lysosomotropic agents like hydroxychloroquine to inhibit autophagic flux in cancer treatment.

Other names

MacroautophagySelective autophagyMitophagy pathwayAutophagic fluxXenophagy

Modulation of autophagy occurs through several mechanisms: mTORC1 inhibition (e.g., Rapamycin) induces the ULK1 complex to initiate autophagosome formation; inhibition of lysosomal acidification (e.g., Chloroquine) prevents the degradation of autophagic cargo; and direct inhibition of kinases like VPS34 or ULK1 blocks early stages of vesicle nucleation (Levy, J. M., et al. (2017). Nature Reviews Cancer, 17(9), 528-542; Mizushima, N., et al. (2011). Cell, 147(4), 728-741).